Medesis Pharma S.A.
Clinical-stage biotech developing treatments using its AONYS® drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Manufacturing
Description
Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-04-21 18:00 |
MEDESIS PHARMA - Mise à disposition du Rapport Financier Annuel 2021
|
French | 311.3 KB | ||
| 2022-04-20 18:30 |
Medesis Pharma : Développement du NanoManganèse pour l’optimisation de la radio…
|
French | 550.7 KB | ||
| 2022-04-20 18:30 |
MEDESIS PHARMA : Development of NanoManganese for the optimization of radiother…
|
English | 517.7 KB | ||
| 2022-04-13 18:00 |
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2021
|
French | 1.3 MB | ||
| 2022-04-05 08:45 |
Medesis Pharma souhaite accélérer le développement de ses produits antinucléair…
|
French | 734.1 KB | ||
| 2022-04-05 08:45 |
Medesis Pharma wishes to accelerate the development of its antinuclear products…
|
English | 633.0 KB | ||
| 2022-04-01 18:00 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 220.3 KB | ||
| 2022-03-24 17:47 |
MEDESIS PHARMA - ENREGISTREMENT AUX ÉTATS-UNIS DU BREVET DE PROTECTION DU FUTU…
|
French | 523.9 KB | ||
| 2022-03-24 17:47 |
MEDESIS PHARMA - U.S. PATENT PROTECTION REGISTRATION OF THE FUTURE DRUG ALLOWIN…
|
English | 426.2 KB | ||
| 2022-03-01 18:00 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 220.5 KB | ||
| 2022-02-07 17:45 |
MEDESIS PHARMA : INCLUSION OF FIRST PATIENTS IN CLINICAL TRIAL IN BRAZIL ON NAN…
|
English | 315.3 KB | ||
| 2022-01-14 18:00 |
MEDESIS PHARMA CONFIRME SON ELIGIBILITE AU PEA-PME
|
French | 170.5 KB | ||
| 2022-01-05 08:00 |
MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2021
|
French | 1.0 MB | ||
| 2022-01-04 18:00 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 221.1 KB | ||
| 2021-12-02 08:00 |
MEDESIS PHARMA PRESENTE UN POSTER SCIENTIFIQUE AU CONGRES SUR LA THERAPIE GENIQ…
|
French | 252.0 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Medesis Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
Peer Companies
